Fatty Acid Supplements Improve Respiratory, Inflammatory and Nutritional Parameters in Adults with Cystic Fibrosis;La suplementación con ácidos grasos mejora parámetros respiratorios, inflamatorios y nutricionales en adultos con fibrosis quística

Archivos de Bronconeumologia

Volumn 46, Issue 2, 2010, Pages 70-77

  Olveira, Gabriel ^a,b   Olveira, Casilda ^a   Acosta, Eva ^a   Espíldora, Francisco ^a   Garrido Sánchez, Lourdes ^c,d   García Escobar, Eva ^a,b   Rojo Martínez, Gemma ^a,b   Gonzalo, Montserrat ^a   Soriguer, Federico ^a,b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Anti inflammatory therapy; Cystic fibrosis; Fatty acids; Inflammation; Lung function; Omega 3; Pulmonary exacerbations; Supplement; Tumor necrosis factor alpha

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LINOLEIC ACID; OMEGA 3 FATTY ACID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CAPSULE; DRUG USE; DYNAMOMETRY; FATTY ACID BLOOD LEVEL; FEMALE; HAND GRIP; HUMAN; LIPID COMPOSITION; LOW DRUG DOSE; LUNG FUNCTION; MALE; NUTRITIONAL PARAMETERS; QUALITY OF LIFE; SPIROMETRY;

EID: 75449111778     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(10)70018-5     Document Type: Article

References (41)

1. Christophe A., and Robberecht E. Directed modification instead of normalization of fatty acid patterns in cystic fibrosis: An emerging concept. Curr Opin Clin Nutr Metab Care. 4 (2001) 111-113
2. Lepage G., Yesair D.W., Ronco N., Champagne J., Bureau N., Chemtob S., et al. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis. J Pediatr. 141 (2002) 178-185
3. Olveira G., Dorado A., Olveira C., Padilla A., Rojo-Martínez G., García-Escobar E., et al. Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis. Br J Nutr. 96 (2006) 343-349
4. Van Biervliet S., Devos M., Delhaye T., Van Biervliet J.P., Robberecht E., and Christophe A. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids. 78 (2008) 109-115
5. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., and Álvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr (-/-) mice. Proc Natl Acad Sci USA. 96 (1999) 13995-14000
6. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med. 350 (2004) 560-569
7. Strandvik B., Gronowitz E., Enlund F., Martinsson T., and Wahlström J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J Pediatr. 138 (2001) 650-655
8. Christophe A., Robberecht E., Franckx H., De Baets F., and van de Pas M. Effect of administration of gamma-linolenic acid on the fatty acid composition of serum phospholipids and cholesteryl esters in patients with cystic fibrosis. Ann Nutr Metab. 38 (1994) 40-47
9. Christophe A., Robberecht E., De Baets F., and Franckx H. Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis. Ann Nutr Metab. 36 (1992) 304-312
10. De Vizia B., Raia V., Spano C., Pavlidis C., Coruzzo A., and Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. J Parenter Enteral Nutr. 27 (2003) 52-57
11. Katz D.P., Manner T., Furst P., and Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition. 12 (1996) 334-339
12. Henderson W.R., Astley S.J., McCready M.M., Kushmerick P., Casey S., Becker J.W., et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J Pediatr. 124 (1994) 400-408
13. Lawrence R.H., and Sorrell T.C. Eicosapentaenoic acid modulates neutrophil leukotriene B4 receptor expression in cystic fibrosis. Clin Exp Immunol. 98 (1994) 12-16
14. Kurlandsky L.E., Bennink M.R., Webb P.M., Ulrich P.J., and Baer L.J. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr Pulmonol. 18 (1994) 211-217
15. Thies N.H. The effect of 12 months' treatment with eicosapentaenoic acid in five children with cystic fibrosis. J Paediatr Child Health. 33 (1997) 349-351
16. Lloyd-Still J.D., Powers C.A., Hoffman D.R., Boyd-Trull K., Lester L.A., Benisek D.C., et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: A randomized, controlled study. Nutrition. 22 (2006) 36-46
17. Jumpsen J.A., Brown N.E., Thomson A.B., Paul Man S.F., Goh Y.K., Ma D., et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J Cyst Fibros. 5 (2006) 77-84
18. Panchaud A., Sauty A., Kernen Y., Decosterd L.A., Buclin T., Boulat O., et al. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomized, crossover placebo controlled trial. Clin Nutr. 25 (2006) 418-427
19. Durieu I., Vericel E., Guichardant D., Roth H., Steghens J.P., Drai J., et al. Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study. J Cyst Fibros. 6 (2007) 320-326
20. Lloyd-Still J.D., Jonson S.B., and Holman R.T. Essential fatty acid status and fluidity of plasma phospholipids in cystic fibrosis infants. Am J Clin Nutr. 54 (1991) 1029-1035
21. Kerem E., Conway S., Elborn S., Heijerman H., and Consensus Committee. Standards of care for patients with cystic fibrosis: A European consensus. J Cystic Fibros. 4 (2005) 7-26
22. Soriguer F., Morcillo S., Cardona F., Rojo-Martínez G., de la Cruz Almaráz M., Ruiz de Adana M., et al. Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr. 136 (2006) 2325-2330
23. Roca J., Sanchis J., Agustí Vidal A., Segarra F., Navajas D., Rodríguez-Roisin R., et al. Spirometric reference values for a Mediterranean population. Bull Eur Physiopathol Respir. 18 (1986) 101-102
24. Sockrider M.M., Swank P.R., Seilheimer D.K., and Schidlow D.W. Measuring clinical status in cystic fibrosis: Internal validity and reliability of a modified NIH score. Pediatr Pulmonol. 17 (1994) 86-96
25. Bhalla M., Turcios N., Aponte V., Jenkins M., Leitman B.S., McCauley D.I., et al. Cystic fibrosis: Scoring system with thin-section CT. Radiology. 179 (1991) 783-788
26. Vendrell M., De Gracia J., Olveira C., Martínez M.A., Girón R., Máiz L., et al. Normativa SEPAR: diagnóstico y tratamiento de las bronquiectasias. Arch Bronconeumol. 44 (2008) 629-640
27. Alastrué A., Sitges A., Jaurrieta M., Puig P., Abad J.M., and Sitges-Creus A. Valoración antropométrica del estado de nutrición: normas y criterios de desnutrición y obesidad. Med Clín (Barc). 80 (1983) 691-699
28. Durnin J.V., and Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: Measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 32 (1974) 77-97
29. Siri W.E. Body composition from fluid spaces and density: Analysis of methods. In: Brozeck J., and Henschel A. (Eds). Techniques for measuring body composition. (1961), National Academy of Sciences, Washington DC 223-244
30. Olveira G., Olveira C., Casado-Miranda E., Padilla A., Dorado A., Rojo G., et al. Markers for the validation of reported dietary intake in adults with cystic fibrosis. J Am Diet Assoc. 109 (2009) 1704-1711
31. Ramsey B.W., Farrel P.M., and Pencharz P. Nutritional assessment and management in cystic fibrosis: A consensus report. The Consensus Committee. Am J Clin Nutr. 55 (1992) 106-108
32. Tinahones F.J., Gómez-Zumaquero J.M., Garrido-Sánchez L., García-Fuentes E., Rojo-Martínez G., Esteva I., et al. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Res. 46 (2005) 452-457
33. Padilla A., Olveira G., Olveira C., Dorado A., Plata A.J., Gaspar I., et al. Validity and reliability of the St. George's Respiratory Questionnaire in adults with cystic fibrosis. Arch Bronconeumol. 43 (2007) 205-211
34. Harris W.S., Pottala J.V., Sands S.A., and Jones P.G. Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr. 86 (2007) 1621-1625
35. Van Biervliet S., Van Biervliet J.P., Robberecht E., and Christophe A. Docosahexaenoic acid trials in cystic fibrosis: A review of the rationale behind the clinical trials. J Cyst Fibros. 4 (2005) 27-34
36. Keen C., Olin A.C., Edentoft A., and Strandvik B. Airway nitric oxide in patients with cystic fibrosis is associated with pancreatic function, pseudomonas infection, and polyunsaturated fatty acids. Chest. 131 (2007) 1857-1864
37. Schmitt-Grohé S., Hippe V., Igel M., Von Bergmann K., Posselt H.G., Krahl A., et al. Serum leptin and cytokines in whole blood in relation to clinical and nutritional status in cystic fibrosis. J Pediatr Gastroenterol Nutr. 43 (2006) 228-233
38. Ionescu A.A., Nixon L.S., Luzio S., Lewis-Jenkins V., Evans W.D., Stone M.D., et al. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. Am J Respir Crit Care Med. 165 (2002) 495-500
39. Martínez-García M.A., Perpiñá-Tordera M., Román-Sánchez P., Soler-Cataluña J.J., Carratalá A., Yago M., et al. The association between bronchiectasis, sistemic inflammation and tumor necrosis factor alpha. Arch Bronconeumol. 44 (2008) 8-14
40. Wood L.G., Fitgerald D.A., Gibson P.G., Cooper D.M., Collins C.E., and Garg M.L. Oxidative stress in cystic fibrosis: Dietary and metabolic factors. J Am Coll Nutr. 20 (2001) 157-165
41. McKarney C., Everard M., and N'Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews. (2007, Issue 4,) Art. No.: CD002201. DOI: 10.1002/14651858.CD002201.pub2